<DOC>
	<DOCNO>NCT01374490</DOCNO>
	<brief_summary>This study conduct evaluate safety tolerability crofelemer 125 mg twice day , take orally , 48 week therapy human immunodeficiency virus-positive ( HIV+ ) subject diarrhea .</brief_summary>
	<brief_title>Safety Tolerability Crofelemer HIV-Associated Diarrhea</brief_title>
	<detailed_description />
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>HIV Enteropathy</mesh_term>
	<criteria>Male female ≥ 18 year old History HIV1 infection On antiretroviral therapeutic regimen treatment HIV1 disease associate condition ( include prophylactic antibiotic Pneumocystis jirovecii infection ) least 4 week prior screen Selfreported presence diarrhea necessitate ADM use least 4 week CD4 count &lt; 100 cells/mm3 Oral temperature great 38.0° C , unintentional weight loss 5.0 kg great prior 2 month Bright red blood per rectum judge anal ( e.g. , hemorrhoid , fissure ) origin Immediate need GI surgery intervention active GI bleeding , pancreatitis , peritonitis , intestinal obstruction , intraabdominal abscess</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>HIV +</keyword>
	<keyword>HIV positive</keyword>
	<keyword>HIV associate diarrhea</keyword>
	<keyword>AIDS</keyword>
	<keyword>Diarrhea</keyword>
</DOC>